Status:

UNKNOWN

Phenotypic Description of Patients With Atypical Clinical Forms of PLA2G6 Mutations

Lead Sponsor:

University Hospital, Clermont-Ferrand

Conditions:

Neuroaxonal Dystrophy, Atypical

Eligibility:

All Genders

Up to 18 years

Brief Summary

Mutations in the PLA2G6 gene are well known in the classical phenotype called infantile neuro-axonal dystrophy (INAD), a severe neurodegenerative disease starting in infancy with homogeneous clinical,...

Detailed Description

Patients with biallelic mutations in PLA2G6 with an atypic INAD starting before 18 years will be recruited after a collaboration call of neuropaediatricians in France. After family consent, a retrospe...

Eligibility Criteria

Inclusion

  • Children with atypical neuroaxonal dystrophy under 18 years at disease-onset
  • with 2 deleterious mutations in the PLA2G6 gene
  • alive or deceased
  • Non-opposition of parents to participate to the retrospective study

Exclusion

  • Classical form of infantile neuroaxonal dystrophy
  • Neuro-axonal dystrophy with adult-onset
  • Opposition of parents to participate to the retrospective study

Key Trial Info

Start Date :

June 1 2022

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 1 2022

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT05440994

Start Date

June 1 2022

End Date

December 1 2022

Last Update

July 1 2022

Active Locations (7)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (7 locations)

1

CHU clermont-ferrand

Clermont-Ferrand, France, 63000

2

CHU Grenoble

Grenoble, France

3

HCL, Hôpital Femme, mère, enfant

Lyon, France

4

CHU Montpellier

Montpellier, France